MX9708727A - Nuevas variantes de la apolipoproteina a-i. - Google Patents
Nuevas variantes de la apolipoproteina a-i.Info
- Publication number
- MX9708727A MX9708727A MX9708727A MX9708727A MX9708727A MX 9708727 A MX9708727 A MX 9708727A MX 9708727 A MX9708727 A MX 9708727A MX 9708727 A MX9708727 A MX 9708727A MX 9708727 A MX9708727 A MX 9708727A
- Authority
- MX
- Mexico
- Prior art keywords
- apolipoprotein
- novel variants
- relates
- variants
- apoloprotein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9506061A FR2734568B1 (fr) | 1995-05-22 | 1995-05-22 | Nouveaux variants de l'apolipoproteine |
PCT/FR1996/000747 WO1996037608A1 (fr) | 1995-05-22 | 1996-05-20 | Nouveaux variants de l'apolipoproteine a-i |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9708727A true MX9708727A (es) | 1997-12-31 |
Family
ID=9479241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9708727A MX9708727A (es) | 1995-05-22 | 1996-05-20 | Nuevas variantes de la apolipoproteina a-i. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0827538A1 (sk) |
JP (1) | JPH11505712A (sk) |
KR (1) | KR19990021828A (sk) |
AU (1) | AU717202B2 (sk) |
BR (1) | BR9608813A (sk) |
CA (1) | CA2218759A1 (sk) |
CZ (1) | CZ291376B6 (sk) |
FR (1) | FR2734568B1 (sk) |
HU (1) | HUP9802926A3 (sk) |
IL (1) | IL118336A0 (sk) |
MX (1) | MX9708727A (sk) |
NO (1) | NO975367D0 (sk) |
SK (1) | SK156397A3 (sk) |
TW (1) | TW434260B (sk) |
WO (1) | WO1996037608A1 (sk) |
ZA (1) | ZA964097B (sk) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
CA2402772A1 (en) * | 2000-03-13 | 2001-09-20 | Amgen Inc. | Apolipoprotein-a-i regulation of t-cell signalling |
CA2428114C (en) | 2000-11-10 | 2013-07-23 | Proteopharma Aps | Apolipoprotein analogues |
WO2003026492A2 (en) | 2001-09-28 | 2003-04-03 | Esperion Therapeutics Inc. | Prevention and treatment of restenosis by local administration of drug |
US7223726B2 (en) * | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
BR0310099A (pt) | 2002-05-17 | 2007-03-20 | Esperion Therapeutics Inc | método para tratar dislipidemia ou uma doença associada com a dislipidemia |
JP4777873B2 (ja) | 2003-02-14 | 2011-09-21 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | 親油性薬物送達ビヒクルおよびこれらの使用方法 |
WO2005097206A2 (en) | 2004-04-06 | 2005-10-20 | Cedars-Sinai Medical Center | Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano |
KR100560102B1 (ko) | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 a-ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
WO2006012632A2 (en) * | 2004-07-23 | 2006-02-02 | Xencor, Inc. | Apolipoprotein a-1 derivatives with altered immunogenicity |
KR100725642B1 (ko) * | 2006-01-20 | 2007-06-07 | 충남대학교산학협력단 | 저밀도 지단백질에 대해 항산화성을 갖는 펩타이드 |
WO2007137400A1 (en) | 2006-06-01 | 2007-12-06 | Institut De Cardiologie De Montreal | Method and compound for the treatment of valvular stenosis |
WO2009158678A1 (en) | 2008-06-27 | 2009-12-30 | Children's Hospital & Research Center At Oakland | Lipophilic nucleic acid delivery vehicle and methods of use therefor |
US8153606B2 (en) * | 2008-10-03 | 2012-04-10 | Opko Curna, Llc | Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1 |
SI2396017T1 (sl) | 2009-02-16 | 2015-12-31 | Cerenis Therapeutics Holding Sa | Mimika apolipoproteina A-1 |
RU2017126088A (ru) | 2011-02-07 | 2019-01-31 | Серени Терапеутикс Холдинг С.А. | Липопротеиновые комплексы и их получение и применения |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9103701D0 (sv) * | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
FR2704556B1 (fr) * | 1993-04-30 | 1995-07-13 | Rhone Poulenc Rorer Sa | Virus recombinants et leur utilisation en thérapie génique. |
-
1995
- 1995-05-22 FR FR9506061A patent/FR2734568B1/fr not_active Expired - Fee Related
-
1996
- 1996-05-20 KR KR1019970708302A patent/KR19990021828A/ko not_active Application Discontinuation
- 1996-05-20 JP JP8535430A patent/JPH11505712A/ja not_active Withdrawn
- 1996-05-20 IL IL11833696A patent/IL118336A0/xx unknown
- 1996-05-20 WO PCT/FR1996/000747 patent/WO1996037608A1/fr not_active Application Discontinuation
- 1996-05-20 EP EP96916216A patent/EP0827538A1/fr not_active Withdrawn
- 1996-05-20 BR BR9608813A patent/BR9608813A/pt not_active Application Discontinuation
- 1996-05-20 CA CA002218759A patent/CA2218759A1/fr not_active Abandoned
- 1996-05-20 HU HU9802926A patent/HUP9802926A3/hu unknown
- 1996-05-20 AU AU59048/96A patent/AU717202B2/en not_active Ceased
- 1996-05-20 MX MX9708727A patent/MX9708727A/es unknown
- 1996-05-20 CZ CZ19973671A patent/CZ291376B6/cs not_active IP Right Cessation
- 1996-05-20 SK SK1563-97A patent/SK156397A3/sk unknown
- 1996-05-22 TW TW085106086A patent/TW434260B/zh active
- 1996-05-22 ZA ZA964097A patent/ZA964097B/xx unknown
-
1997
- 1997-11-21 NO NO975367A patent/NO975367D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO975367L (no) | 1997-11-21 |
IL118336A0 (en) | 1996-09-12 |
FR2734568A1 (fr) | 1996-11-29 |
BR9608813A (pt) | 1999-02-17 |
ZA964097B (en) | 1996-12-06 |
HUP9802926A3 (en) | 2001-08-28 |
HUP9802926A2 (hu) | 1999-03-29 |
SK156397A3 (en) | 1998-07-08 |
WO1996037608A1 (fr) | 1996-11-28 |
FR2734568B1 (fr) | 1997-06-20 |
AU5904896A (en) | 1996-12-11 |
EP0827538A1 (fr) | 1998-03-11 |
TW434260B (en) | 2001-05-16 |
CZ291376B6 (cs) | 2003-02-12 |
JPH11505712A (ja) | 1999-05-25 |
CA2218759A1 (fr) | 1996-11-28 |
NO975367D0 (no) | 1997-11-21 |
CZ367197A3 (cs) | 1998-03-18 |
KR19990021828A (ko) | 1999-03-25 |
AU717202B2 (en) | 2000-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9708727A (es) | Nuevas variantes de la apolipoproteina a-i. | |
HUP9801639A3 (en) | Genetic sequences and proteins related to alzheimer's disease, and uses therefor | |
ZA941773B (en) | Therapeutic uses of bactericidal/permeability increasing protein products | |
HUP0002701A3 (en) | Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides | |
AU4770596A (en) | Improved therapeutic compositions comprising bactericidal/permeability-increasing (bpi) protein products | |
FR2792202B1 (fr) | Extrait peptidique de lupin et composition pharmaceutique ou cosmetique ou nutraceutique comprenant un tel extrait | |
ATE204297T1 (de) | Peptidanaloge des lh-rh, ihre verwendungen und die sie enthaltenden pharmazeutischen zusammensetzungen | |
HK1043937A1 (zh) | Bpi蛋白質產品的人類醫療用途 | |
IL114407A0 (en) | Novel peptides and pharmaceutical compositions comprising them | |
BG103968A (en) | Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity | |
HK1029928A1 (en) | Pharmaceutical compositions of peptides having lowsolubility in physiological medium. | |
ZA966047B (en) | Therapeutic agents. | |
FI942938A0 (fi) | Soijaproteiini tai -hydrolysaatit farmaseuttisissa koostumuksissa bioaktiivisten peptidien suojana entsymaattista inaktivoitumista vastaan | |
DE59408697D1 (de) | Multicistronische expression rekombinanter gene in bakterienzellen | |
CA2247998A1 (en) | Fragments of cr1 and their use | |
IL109911A0 (en) | Enhanced expression of peptide molecules | |
TH24179EX (th) | ตู้เย็น | |
TH22123EX (th) | ตู้เย็น | |
TH21349EX (th) | ขวด | |
TH20739EX (th) | ตู้เย็น | |
TH26996EX (th) | เก้าอี้ | |
TH13895EX (th) | ผลไม้ประดิษฐ์ | |
TH13896EX (th) | ผลไม้ประดิษฐ์ | |
TH48035EX (th) | ขวด | |
TH48036EX (th) | ขวด |